A few weeks ago the New York Times published an interesting article about Calico, a Google backed biotech company. Arthur D. Levinson, former Genentech CEO, will assume that position for Calico as well. Calico is focused on slowing aging but is approaching the problem from a basic science perspective. The goal is to identify novel therapeutic targets overtime that the company will eventually develop compounds around. Calico has this luxury of time due to the financial backing from Google and others. I think it is an interesting way to approach drug development, and while similar approaches have been used before it will be exciting to see how Google fares.